Resistance to activated protein C in women using oral contraceptives

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue 5, 1998, Pages 423-430

  Spannagl, Michael ^a   Dick, Andrea ^a   Assmann, Anita ^b   Heinemann, Lothar ^b,c,d   Schramm, Wolfgang ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ZEG Ctr Epidemiol Hlth Res B   (Germany)

^c MCGILL UNIVERSITY   (Canada)

^d Potsdam Inst P   (Germany)

Author keywords

Acquired APC resistance; Bavarian Thyromboembolic Risk Study; Factor V Leiden; Factor VIII: C; Oral contraceptives

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 8; ORAL CONTRACEPTIVE AGENT;

ADULT; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM;

EID: 0031757019     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996034     Document Type: Conference Paper

References (22)

1. Dahlbäck B, Carlson M, Sevensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterised by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated Protein C. Proc Natl Acad Sci USA 1993;90:1004-1008
2. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thromhophilia Study. Lancet 1993;342:1503-1506
3. Rosen SB, Sturk A. Activated protein C resistance - a major risk factor for thrombosis. Eur J Clin Chem Clin Biochem 1997; 35:501-516
4. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67
5. Dahlbäck B. New molecular insights into the genetics of thromhophilia. Thromb Haemostas 1995;74:139-148
6. Green D, Maliekel K, Sushko E, Akhtar R, Soff G. Activated protein C resistance in cancer patients. Haemostasis 1997;27:112-118
7. Olivieri O, Friso S, Manzato F, et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995;92:465-470
8. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: Result of international multicentre case-control study. Lancet 1995;346:1575-1581
9. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated Protein C in degradation of factor VIIIa. J Biol Chem 1994;269:19735-19738
10. Varadi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz H. Factor V enhances the cofactor function of protein S in the APC mediated inactivation of factor VIII: Influence of the factor V R506Q mutation. Thromb Haemostas 1996;76:208-214
11. Tans G, Nicolaes AF, Rosing J. Regulation of thrombin formation by activated protein C: Effect of the factor V Leiden mutation. Semin Hematol 1997;34:244-255
12. Schramm W, Dick A, Spannagl M, et al. Bavarian study on clinical relevance of thromboembolic risk factors in women taking oral contraceptives. Ann Haematol 1997;74:A108 (Abst)
13. Kraus M, Noah M, Fickenscher K. The PCAT-A simple screening assay for assessing the functionality of the protein C anti-coagulant pathway. Thromb Res 1995;79:217-222
14. Dati F, Hafner G, Erbes H, et al. Proc global: The first functional screening assay for the complete protein C pathway. Clin Chem 1997;43:1719-1723
15. Varadi K, Moritz B, Lang H, et al. A chromogenic assay for activated protein C resistance. Br J Haematol 1995;90:884-891
16. Dahlbäck B. Molecular genetics of thrombophilia: Factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulablc state. J Lab CHn Med 1995;125: 566-571
17. Kraus M, Zander N, Fickenscher K. Coagulation assay with improved specificity to factor V mutants insensitive to activated protein C. Thromb Res 1995;80:255-264
18. Henkens CM, Bom VJ, Seinen AJ, van der Meer J. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemostas 1995;73:402-404
19. Olivieri O, Friso S, Manzato F, et al. Resistance to activated protein C, associated with oral contraceptive use; effect of formulations, duration of assumption, and doses of oestroprogestins. Contraception 1996;54:149-152
20. Rosing J, Tans G, Nicolaes AF, et al. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997;97:233-238
21. Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemostas 1997;78:315-326
22. Hemker HC, Widders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemostas 1993; 70:617-624